Search research articles
Contact Us
Filters
Showing results (121-130 of 129) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 129 results.
American Journal of Human Genetics
|
March 6, 2012
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region
Jong-Min Lee, Tammy Gillis, Jayalakshmi Srinidhi Mysore, et al.
Human Genetics
|
July 25, 2012
Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset
Eliana Marisa Ramos, Jeanne C Latourelle, Ji-Hyun Lee, et al.
Neurogenetics
|
May 7, 2013
Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset
Eliana Marisa Ramos, Jeanne C Latourelle, Tammy Gillis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 24, 2017
KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients
Luisa Quinti, Sharadha Dayalan Naidu, Ulrike Träger, et al.
Neurology
|
February 11, 2012
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
J-M Lee, E M Ramos, J-H Lee, et al.
Biochemical and Biophysical Research Communications
|
July 10, 2012
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease
Ji-Hyun Lee, Jong-Min Lee, Eliana Marisa Ramos, et al.
American Journal of Human Genetics
|
August 6, 2003
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study
Jian-Liang Li, Michael R Hayden, Elisabeth W Almqvist, et al.
BMC Medical Genetics
|
August 18, 2006
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study
Jian-Liang Li, Michael R Hayden, Simon C Warby, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 129) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 129 results.
American Journal of Human Genetics
|
March 6, 2012
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region
Jong-Min Lee, Tammy Gillis, Jayalakshmi Srinidhi Mysore, et al.
Human Genetics
|
July 25, 2012
Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset
Eliana Marisa Ramos, Jeanne C Latourelle, Ji-Hyun Lee, et al.
Neurogenetics
|
May 7, 2013
Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset
Eliana Marisa Ramos, Jeanne C Latourelle, Tammy Gillis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 24, 2017
KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients
Luisa Quinti, Sharadha Dayalan Naidu, Ulrike Träger, et al.
Neurology
|
February 11, 2012
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
J-M Lee, E M Ramos, J-H Lee, et al.
Biochemical and Biophysical Research Communications
|
July 10, 2012
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease
Ji-Hyun Lee, Jong-Min Lee, Eliana Marisa Ramos, et al.
American Journal of Human Genetics
|
August 6, 2003
A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study
Jian-Liang Li, Michael R Hayden, Elisabeth W Almqvist, et al.
BMC Medical Genetics
|
August 18, 2006
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study
Jian-Liang Li, Michael R Hayden, Simon C Warby, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 13